EGFR anticorps

N° du produit ABIN371623

Détail du produit anti-EGFR anticorps

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivité: Humain

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro))

Specificité: This antibody reacts with human EGFR (150 kDa). It reacts specifically with the EGFR but does not react with Her-2 recombinant protein.

Attributs du produit: Synonyms: Epidermal growth factor receptor, EGF Receptor, erbB-1, c-ErbB-1, Receptor tyrosine-proteinkinase erbB-1, Proto-oncogene c-ErbB-1

Purification: Purified

Immunogène: Recombinant human EGFR.

Clone: SB41a

Isotype: IgG2a

Information d'application

Indications d'application: Western Blot: < / = 1-2 μg/mL. Immunohistochemistry (FS or cultured and Methanol-Fixed Cell Lines): 10 μg/mL
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 0.1 mg/mL

Buffer: 100 mM Borate buffered saline, pH 8.0 without preservatives.

Agent conservateur: Without preservative

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Date de péremption: 12 months

Détails sur EGFR

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Autre désignation: EGFR / ERBB1 (EGFR Produits)

Synonymes: anticorps C-erb, anticorps CG10079, anticorps D-EGFR, anticorps D-Egf, anticorps DEGFR, anticorps DER, anticorps DER flb, anticorps DER/EGFR, anticorps DER/faint little ball, anticorps DER/top, anticorps DER/torpedo, anticorps DER1, anticorps DEgfr, anticorps Degfr, anticorps Der, anticorps DmHD-33, anticorps Dmel\\CG10079, anticorps EFG-R, anticorps EGF-R, anticorps EGFR, anticorps EGFr, anticorps EGfr, anticorps EK2-6, anticorps Egf, anticorps Egf-r, anticorps EgfR, anticorps El, anticorps Elp, anticorps Elp-1, anticorps Elp-B1, anticorps Elp-B1RB1, anticorps HD-33, anticorps TOP, anticorps Torpedo/DER, anticorps Torpedo/Egfr, anticorps c-erbB, anticorps d-egf-r, anticorps dEGFR, anticorps dEGFR1, anticorps dEgfr, anticorps der, anticorps egfr, anticorps flb, anticorps l(2)05351, anticorps l(2)09261, anticorps l(2)57DEFa, anticorps l(2)57EFa, anticorps l(2)57Ea, anticorps mor1, anticorps top, anticorps top/DER, anticorps top/flb, anticorps torpedo/Egfr, anticorps torpedo/egfr, anticorps EGFR12, anticorps EGFR15, anticorps egfr1, anticorps Erbb2, anticorps ERBB, anticorps ERBB1, anticorps HER1, anticorps PIG61, anticorps mENA, anticorps ErbB-1, anticorps Errp, anticorps 9030024J15Rik, anticorps AI552599, anticorps Erbb, anticorps Errb1, anticorps Wa5, anticorps wa-2, anticorps wa2, anticorps epidermal growth factor receptor, anticorps Epidermal growth factor receptor, anticorps epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), anticorps EGFR, anticorps Egfr, anticorps egfra, anticorps egfr1, anticorps LOC5564544

Sujet: Epidermal growth factor receptor (EGFR) is a transmembrane receptor for epidermal growth factor (EGF). It is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB -1), HER2/c-neu (ErbB-2) Her 3 (ErbB-3 and Her 4 (ErbB-4). EGFR exists on the cell surface as inactive monomers and is activated by binding of its specific ligands, including EGF, transforming growth factor alpha (TGFalpha), or others. Upon activation, EGFR can pair with another EGFR to form an active homodimer or an EGFR may pair with another member of the ErbB receptor family, such as Her 2/c-neu, to create a heterodimer. Evidence also suggests that a cluster of active EGFR can form. (Ref.1-3) The binding of ligand stimulates the intrinsic protein-tyrosine kinase activity of EGFR which initiates a signal transduction cascade leading to DNA synthesis and cell proliferation. The kinase activity can also result in autophosphorylation of the five tyrosine residues in the C-terminal domain of EGFR. Autophosphorylation elicits downstream activation and signaling events of other proteins that are often distinct from those activated by the kinase domain of EGFR. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in this manner. Mutations that lead to EGFR overexpression or overactivity have been associated with many common solid human squamous cell carcinomas including breast, brain, bladder, lung, gastric, head and neck, esophagus, cervix, vulva, ovary, and endometrium. (Ref.4-7) EGFR and ErbB -2 are particularly important in breast cancer because increased production or activation has been associated with poor prognosis. Tumor aggressiveness and patient outcome can be directly correlated to the production levels. Inhibitors of EGFR represent an emerging new class of anti-cancer drugs that target the underlying molecular changes involving oncogenes and tumor suppressor genes, genes that play critical roles in the conversion of normal cells into a cancerous state.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

ID gène: 1956

UniProt: P00533

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins